Skip to content

Experimental study on the application of intravenous lidocaine infusion in ERAS management for gastrointestinal surgery under general anesthesia

Experimental study on the application of intravenous lidocaine infusion in ERAS management for gastrointestinal surgery under general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092459
Enrollment
Unknown
Registered
2024-11-18
Start date
2024-11-18
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal surgery

Interventions

Lidocaine group:Before induction of anesthesia, lidocaine was injected 1.5mg / kg and the operation was started 30 minutes later. The anesthesia was maintained at a rate of 1.5mg / kg / h (if the pati
Saline group:Isovolume saline was administered in the remaining isolidocaine group (including intravenous start time, start of continuous pump infusion, and stop time).

Sponsors

And Sichuan Provincial Academy of Medical Sciences. Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Patients scheduled for elective gastrointestinal surgery; 2) ASA I-II level; 3) Age 18-65 years; 4) Surgery duration of 2-4 hours; 5) Willing to receive lidocaine intravenously, informed and willing to participate in this study, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Allergy or contraindications to lidocaine; 2) conduction block arrhythmia, sinus bradycardia, preexcitation syndrome, AS syndrome, atrial fibrillation, etc.; 3) Severe hepatic and renal dysfunction; 4) Serious mental illness, such as schizophrenia, depression, dementia, etc.; 5) Neuromuscular diseases; 6) Patients with difficult airway; 7) Pregnant women; weight 100kg; 8) History of chronic analgesics, long-term history of opioid drugs, alcohol or medication Abuse of things; 9) Taking other trial drugs three months before the study, participated in or are participating in other clinical trials; 10) Unable to cooperate with the study for any reason or the investigator considers unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Protein levels;

Secondary

MeasureTime frame
Postoperative pain VAS score;Postoperative inflammatory markers after 48 hours;

Countries

China

Contacts

Public ContactXi Yang

Anesthesiology Department of Sichuan Provincial People's Hospital

552309660@qq.com+86 177 0813 0271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026